David R. Bauer

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $225 million initial public offering by Orchard Therapeutics…

Davis Polk is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from Strongbridge Biopharma Plc. Novo Nordisk will also acquire newly issued…

Davis Polk advised the representatives of the underwriters in connection with the $50 million initial public offering of 6,250,000 ordinary shares of Gamida Cell Ltd. The ordinary…

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by AbbVie Inc. of $6 billion aggregate principal amount of senior notes in four…

Davis Polk advised Zai Lab Limited in connection with its first follow-on offering of $150 million of American Depositary Shares representing 7,500,000 ordinary shares of the company. The…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Zoetis Inc. of $300 million aggregate principal amount of its floating-rate senior notes…

Davis Polk advised the representatives of the underwriters in connection with the $175.5 million offering of 2,700,000 shares of common stock of REGENXBIO Inc. The common stock is listed on…

Davis Polk advised the underwriters and the joint global coordinators in the public offering of BeiGene, Ltd. on the Hong Kong Stock Exchange. The gross proceeds from the offering…

Davis Polk advised AC Immune SA in connection with its $117.5 million U.S. follow-on public offering. AC Immune sold 8,500,000 of its newly issued common shares and subscription rights…

Davis Polk advised the representatives of the several underwriters in connection with the $60 million initial public offering of common stock of Constellation Pharmaceuticals, Inc. The…